TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA et al.
Cancer Biomarkers : Section a of Disease Markers, 2022